Boston Scientific has agreed to a $62.5 million deal with Xlumena and its Axios line of biliary devices, putting at least another $12.5 million on the table in potential milestones, according to an article via  The move establishes both Boston Scientific and Xlumena’s commitment to advancing the field of interventional endoscopic ultrasound therapeutics.  For more information on this acquisition, please visit: